User profiles for Young-Hak Kim
 | Young-hak Kim울산대 서울아산병원 교수 Verified email at amc.seoul.kr Cited by 35808 |
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled …
…, H Hayashi, T Hida, K Kanazawa, S Kanda, YH Kim… - The Lancet, 2019 - thelancet.com
Background Most patients with small-cell lung cancer (SCLC) have extensive-stage disease
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …
at presentation, and prognosis remains poor. Recently, immunotherapy has demonstrated …
[HTML][HTML] Randomized trial of stents versus bypass surgery for left main coronary artery disease
SJ Park, YH Kim, DW Park, SC Yun… - … England Journal of …, 2011 - Mass Medical Soc
Background Percutaneous coronary intervention (PCI) is increasingly used to treat unprotected
left main coronary artery stenosis, although coronary-artery bypass grafting (CABG) has …
left main coronary artery stenosis, although coronary-artery bypass grafting (CABG) has …
Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial
T Hida, H Nokihara, M Kondo, YH Kim, K Azuma… - The Lancet, 2017 - thelancet.com
Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma
kinase (ALK), showed promising efficacy and tolerability in the single-arm phase 1/2 AF-…
kinase (ALK), showed promising efficacy and tolerability in the single-arm phase 1/2 AF-…
[HTML][HTML] Duration of dual antiplatelet therapy after implantation of drug-eluting stents
Background The potential benefits and risks of the use of dual antiplatelet therapy beyond a
12-month period in patients receiving drug-eluting stents have not been clearly established. …
12-month period in patients receiving drug-eluting stents have not been clearly established. …
Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual …
Background Numerous randomised trials have compared coronary artery bypass grafting (CABG)
with percutaneous coronary intervention (PCI) for patients with coronary artery disease…
with percutaneous coronary intervention (PCI) for patients with coronary artery disease…
[HTML][HTML] Stents versus coronary-artery bypass grafting for left main coronary artery disease
Background Several studies have compared the treatment effects of coronary stenting and
coronary-artery bypass grafting (CABG). However, there are limited data regarding the long-…
coronary-artery bypass grafting (CABG). However, there are limited data regarding the long-…
Sirolimus-eluting stent implantation for unprotected left main coronary artery stenosis: comparison with bare metal stent implantation
Objectives : This study was designed to compare the clinical and angiographic outcomes of
sirolimus-eluting stent (SES) and bare metal stent (BMS) implantation for unprotected left …
sirolimus-eluting stent (SES) and bare metal stent (BMS) implantation for unprotected left …
Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up
Despite concerns regarding the long-term safety of drug-eluting stent (DES) implantation
because of late-onset stent thrombosis, the actual incidence of stent thrombosis after 1 year is …
because of late-onset stent thrombosis, the actual incidence of stent thrombosis after 1 year is …
Impact of intravascular ultrasound guidance on long-term mortality in stenting for unprotected left main coronary artery stenosis
Background— Although intravascular ultrasound (IVUS) guidance has been useful in stenting
for unprotected left main coronary artery stenosis, its impact on long-term mortality is still …
for unprotected left main coronary artery stenosis, its impact on long-term mortality is still …
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled …
…, Y Hosomi, H Sakai, Y Takiguchi, YH Kim… - The Lancet …, 2019 - thelancet.com
Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …